The content on this site is intended for healthcare professionals only
Women with breast cancer aged 35 or younger were more likely than older women to achieve a pathological complete response after neoadjuvant chemotherapy, according to data presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium.
Read more in ecancernews.
Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer
Endocrine therapy plus trastuzumab and pertuzumab shows excellent survival outcomes in HR and HER2 positive early BC
Hormonal receptor positive breast cancer adjuvant and metastatic indications
Trastuzumab deruxtecan significantly improves PFS In breast cancer patients previously treated with endocrine therapy
Adjuvant avelumab versus control does not significantly improve DFS but does improve OS in high-risk TNBC patients
HER2DX assay and survival outcomes: An individual-patient level meta-analysis of 2,031 patients with HER2-positive BC
Low-dose olanzapine after highly emetogenic chemotherapy can be the new standard of care for solid tumours
Breast Cancer
OncoAlert round up July 28th to August 3rd, 2023
